arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Immix Biopharma, Inc.

IMMX Health Care Biotechnology: Pharmaceutical Preparations
$13.91
Today
as of Sep 4, 16:50 ET
Last 30 days +64.81% Jul 28 → Sep 04
$7.67 $9.49 $11.32 $13.15 $14.97 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$13.68
High
$14.09
Low
$13.60
Volume
$1M
Avg Vol
$1M
Mkt Cap
$941M
P/E (TTM)
—
Beta
—
52w High
$15.10
52w Low
$1.94
Div Yield
—
Shares Out
$72M

Recent Press Releases & News last 60 days · 3 items

Aug 11 · 09:31 MT Newswires
Morgan Stanley Adjusts PT on Immix Biopharma to $19 From $20, Maintains Overweight Rating
Aug 4 · 13:15 PR GlobeNewswire
Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Jul 22 · 11:19 MT Newswires
Needham Initiates Immix Biopharma at Buy With $21 Price Target

Overview

52-week range
$1.94
$15
91% of range
Avg surprise (last 3)
+14.8%
Avg reaction (last 2)
-3.2%
50% positive
Latest IV / EM
112%
EM ±17.4% · $15 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.74$-0.47$-0.20$0.08$0.35 Actual $-0.18Actual $-0.24Actual $-0.23Actual $-0.22Actual $-0.15Actual $-0.24Actual $-0.15Est $-0.23Actual $-0.22Est $-0.21Actual $-0.24Actual $-0.18Est $-0.21Actual $-0.18 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-12M$-10M$-8M$-6M$-5M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.18 — — — — financials
Thu May 7, 2026Mar/2026 $-0.18 $-0.21 +14.3% -20.0% -7.6% earnings
Tue Sep 30, 2025Sep 2025 $-0.24 — — — — financials
Fri Aug 8, 2025Jun/2025 $-0.22 $-0.21 -4.8% — — earnings
Thu May 8, 2025Mar/2025 $-0.15 $-0.23 +34.8% — +1.2% earnings
Mon Sep 30, 2024Sep 2024 $-0.24 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.15 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.22 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.23 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.24 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.18 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-12M$-11M—$-8M$-7M$-5M—$-7M
Net income$-12M$-10M—$-8M$-7M$-5M—$-7M
EPS (diluted)$-0.18$-0.18—$-0.24$-0.22$-0.15—$-0.24

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$225M$79M$94M$16M$12M$16M$18M$20M
Inventory————————
Total current assets$234M$92M$101M$17M$12M$17M$20M$23M
Total assets$239M$96M$105M$20M$16M$20M$23M$25M
Long-term debt————————
Total liabilities$10M$11M$11M$12M$11M$10M$10M$8M
Total equity$229M$84M$94M$8M$5M$10M$13M$18M

Implied volatility — last 90 days

79%164%249%334%419% Jun 07 — IV 102% · EM ±14.2%Jun 08 — IV 132% · EM ±17.5%Jun 09 — IV 229% · EM ±28.7%Jun 10 — IV 192% · EM ±22.7%Jun 11 — IV 179% · EM ±19.8%Jun 12 — IV 226% · EM ±23.1%Jun 15 — IV 302% · EM ±21.8%Jun 16 — IV 416% · EM ±24.6%Jun 17 — IV 420% · EM ±17.5%Jun 19 — IV 197% · EM ±43.6%Jun 22 — IV 185% · EM ±38.6%Jun 23 — IV 112% · EM ±23.0%Jun 24 — IV 104% · EM ±20.9%Jun 25 — IV 95% · EM ±18.5%Jun 26 — IV 110% · EM ±21.0%Jun 29 — IV 120% · EM ±21.2%Jun 30 — IV 90% · EM ±15.5%Jul 01 — IV 99% · EM ±16.5%Jul 02 — IV 91% · EM ±14.7%Jul 03 — IV 94% · EM ±14.7%Jul 06 — IV 100% · EM ±13.8%Jul 07 — IV 189% · EM ±25.0%Jul 08 — IV 190% · EM ±23.8%Jul 09 — IV 379% · EM ±44.8%Jul 10 — IV 204% · EM ±22.5%Jul 13 — IV 176% · EM ±14.7%Jul 14 — IV 201% · EM ±14.5%Jul 15 — IV 330% · EM ±19.5%Jul 16 — IV 179% · EM ±7.5%Jul 20 — IV 119% · EM ±28.1%Jul 21 — IV 104% · EM ±24.3%Jul 22 — IV 98% · EM ±22.3%Jul 23 — IV 139% · EM ±31.2%Jul 24 — IV 125% · EM ±27.6%Jul 27 — IV 132% · EM ±27.5%Jul 28 — IV 114% · EM ±23.4%Jul 29 — IV 189% · EM ±37.9%Jul 30 — IV 176% · EM ±34.5%Jul 31 — IV 122% · EM ±23.4%Aug 03 — IV 124% · EM ±22.0%Aug 04 — IV 118% · EM ±20.3%Aug 05 — IV 108% · EM ±18.1%Aug 06 — IV 80% · EM ±12.9%Aug 07 — IV 109% · EM ±17.1%Aug 10 — IV 91% · EM ±12.6%Aug 11 — IV 241% · EM ±31.8%Aug 12 — IV 347% · EM ±43.5%Aug 13 — IV 163% · EM ±19.2%Aug 14 — IV 173% · EM ±19.1%Aug 17 — IV 290% · EM ±24.2%Aug 18 — IV 293% · EM ±21.2%Aug 19 — IV 186% · EM ±11.0%Aug 20 — IV 409% · EM ±17.1%Aug 24 — IV 98% · EM ±20.4%Aug 25 — IV 98% · EM ±20.0%Aug 26 — IV 90% · EM ±17.9%Aug 27 — IV 84% · EM ±16.4%Aug 28 — IV 117% · EM ±22.4%Aug 31 — IV 126% · EM ±22.3%Sep 01 — IV 104% · EM ±17.8%Sep 02 — IV 101% · EM ±16.8%Sep 03 — IV 135% · EM ±21.9%Sep 04 — IV 112% · EM ±17.4%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in